Search Result

Pathways Recommended:	Anti-infection

Results for "

human immunodeficiency virus type 1 infection

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV (13) CCR (2) CXCR (1) Cyclic GMP-AMP Synthase (1) HIV Integrase (1) HIV Protease (4) IFNAR (1) Isotope-Labeled Compounds (1) Reverse Transcriptase (2) STING (1)
By Research Areas:	Cancer (2) Infection (15) Inflammation/Immunology (1)
Oligonucleotides:	CpG ODNs (1)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: HIV C-type Lectin-like Receptors (CTLRs) PCSK9 Scavenger Receptor Class B type I (SR-BI）

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111964

Lenacapavir 15+ Cited Publications GS-6207	HIV	Infection
Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .

HY-111964A

Lenacapavir sodium 15+ Cited Publications GS-6207 sodium	HIV	Infection
Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .

HY-171692

G3-YSD	Cyclic GMP-AMP Synthase IFNAR STING	Infection
G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger STING-dependent IFN-α/β secretion. G3-YSD acts as a viral mimic to replace actual viral DNA . G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection .

HY-106958

Talviraline HBY 097	HIV Reverse Transcriptase	Infection
Talviraline is a non-nucleoside reverse transcriptase (NNRT) inhibitor that is primarily used to inhibit the replication of human immunodeficiency virus type 1 (HIV-1). Talviraline inhibits the viral replication process by binding to a specific site of HIV-1 reverse transcriptase (RT). Talviraline can be used to study the potential countermeasures and safety of HIV-1 infection .

HY-P35433

Tifuvirtide T-1249	HIV	Inflammation/Immunology
Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .

HY-139158

Ainuovirine	HIV	Infection
Ainuovirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Ainuovirine inhibits HIV replication by non-competitively binding to HIV reverse transcriptase and blocking the reverse transcription process of viral RNA. Ainuovirine can be used for human immunodeficiency virus (HIV) type 1 infection .

HY-B0155

Vicriviroc SCH 417690; SCH-D; MK-7690 free base	CCR HIV	Infection Cancer
Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC₅₀ of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC₅₀ values of 0.91 nM and 16 nM,,respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer .

HY-105386

HI-280	HIV Reverse Transcriptase	Infection
HI-280 is a **human immunodeficiency virus type 1 (HIV-1) reverse transcriptase** inhibitor. HI-280 can be used for the research of infection .

HY-125494

Droxinavir hydrochloride SC-55389A	HIV HIV Protease	Infection
Droxinavir hydrochloride (SC-55389A) is an HIV-1 protease inhibitor. Droxinavir hydrochloride binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir hydrochloride can be used in studies related to human immunodeficiency virus type 1 infection .

HY-B0155B

Vicriviroc malate SCH 417690 malate; SCH-D malate; MK-7690	CCR HIV	Infection Cancer
Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC₅₀ of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC₅₀ values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer .

HY-P10429

RCP168	CXCR	Infection
RCP168 is a highly selective and affinity CXCR4 receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via CXCR4 receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between CXCR4 receptor and other chemical factor receptors .

HY-182316

P-1946	HIV Protease HIV	Infection
P-1946 is a HIV protease inhibitor with a human HIV-1 protease K_i of 2.600 nM. P-1946 has potent and selective in vitro antiviral activity and retains full antiviral activity against HIV isolates resistant to commercially available protease inhibitors. P-1946 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .

HY-125494A

Droxinavir SC-55389A free base	HIV HIV Protease	Infection
Droxinavir (SC-55389A free base) is an HIV-1 protease inhibitor. Droxinavir binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir can be used in studies related to human immunodeficiency virus type 1 infection .

HY-126120

BILA 1906 BS	HIV HIV Protease	Infection
BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .

HY-182678

L-731988	HIV Integrase	Infection
L-731988 is an inhibitor targeting HIV-1 integrase. L-731988 inhibits HIV-1 replication by blocking integrase function. L-731988 exhibits ED₅₀ values ranging from 0.5 μM to 3.14 μM against various HIV-1 isolates. L-731988 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .

HY-111964S1

Lenacapavir-d5 GS-6207-d₅	Isotope-Labeled Compounds HIV	Infection
Lenacapavir-d₅ (GS-6207-d₅) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .

Cat. No.	Product Name	Target	Research Area

HY-P35433

Tifuvirtide T-1249	HIV	Inflammation/Immunology
Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .

HY-P10429

RCP168	CXCR	Infection
RCP168 is a highly selective and affinity CXCR4 receptor antagonist (IC₅₀=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via CXCR4 receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between CXCR4 receptor and other chemical factor receptors .

Cat. No.	Product Name	Chemical Structure

HY-111964S1

Lenacapavir-d5
Lenacapavir-d₅ (GS-6207-d₅) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .

Lenacapavir-d5

Lenacapavir-d₅ (GS-6207-d₅) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .

Cat. No.	Product Name		Classification

HY-171692

G3-YSD		CpG ODNs
G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger STING-dependent IFN-α/β secretion. G3-YSD acts as a viral mimic to replace actual viral DNA . G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.